AR124434A1 - Métodos para la detección de anticuerpos antifármaco contra anticuerpos factor xi y/o factor xia - Google Patents

Métodos para la detección de anticuerpos antifármaco contra anticuerpos factor xi y/o factor xia

Info

Publication number
AR124434A1
AR124434A1 ARP210103581A ARP210103581A AR124434A1 AR 124434 A1 AR124434 A1 AR 124434A1 AR P210103581 A ARP210103581 A AR P210103581A AR P210103581 A ARP210103581 A AR P210103581A AR 124434 A1 AR124434 A1 AR 124434A1
Authority
AR
Argentina
Prior art keywords
factor
factor xia
ada
antibody
antibodies
Prior art date
Application number
ARP210103581A
Other languages
English (en)
Spanish (es)
Inventor
Debra A Freedholm
Daniel M Bloomfield
Royston J Glasspool
Jonathan E Freeman
Yasser Khder
Original Assignee
Anthos Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthos Therapeutics Inc filed Critical Anthos Therapeutics Inc
Publication of AR124434A1 publication Critical patent/AR124434A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96452—Factor XI (3.4.21.27)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP210103581A 2020-12-18 2021-12-20 Métodos para la detección de anticuerpos antifármaco contra anticuerpos factor xi y/o factor xia AR124434A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063127536P 2020-12-18 2020-12-18

Publications (1)

Publication Number Publication Date
AR124434A1 true AR124434A1 (es) 2023-03-29

Family

ID=82059801

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103581A AR124434A1 (es) 2020-12-18 2021-12-20 Métodos para la detección de anticuerpos antifármaco contra anticuerpos factor xi y/o factor xia

Country Status (19)

Country Link
US (1) US20240077497A1 (https=)
EP (1) EP4264278A4 (https=)
JP (1) JP2023554347A (https=)
KR (1) KR20230121120A (https=)
CN (1) CN116601491A (https=)
AR (1) AR124434A1 (https=)
AU (1) AU2021401421A1 (https=)
CA (1) CA3199482A1 (https=)
CL (1) CL2023001709A1 (https=)
CO (1) CO2023008150A2 (https=)
CR (1) CR20230313A (https=)
CU (1) CU20230031A7 (https=)
EC (1) ECSP23053645A (https=)
IL (1) IL302904A (https=)
JO (1) JOP20230137A1 (https=)
MX (1) MX2023007281A (https=)
PE (1) PE20231679A1 (https=)
TW (1) TW202242414A (https=)
WO (1) WO2022133263A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025523802A (ja) * 2022-07-13 2025-07-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 分析物を検出するための弱酸性免疫アッセイ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
MX2020004921A (es) * 2017-11-29 2020-08-27 Hoffmann La Roche Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo.
WO2020231992A1 (en) * 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays

Also Published As

Publication number Publication date
JOP20230137A1 (ar) 2023-06-14
ECSP23053645A (es) 2023-08-31
CL2023001709A1 (es) 2023-11-17
CU20230031A7 (es) 2024-02-07
WO2022133263A1 (en) 2022-06-23
TW202242414A (zh) 2022-11-01
CR20230313A (es) 2023-08-18
AU2021401421A1 (en) 2023-06-22
US20240077497A1 (en) 2024-03-07
IL302904A (en) 2023-07-01
EP4264278A4 (en) 2024-11-27
AU2021401421A9 (en) 2024-10-24
EP4264278A1 (en) 2023-10-25
CA3199482A1 (en) 2022-06-23
JP2023554347A (ja) 2023-12-27
KR20230121120A (ko) 2023-08-17
CN116601491A (zh) 2023-08-15
MX2023007281A (es) 2023-09-04
CO2023008150A2 (es) 2023-06-30
PE20231679A1 (es) 2023-10-19

Similar Documents

Publication Publication Date Title
Eskut et al. New results from a search for νμ→ ντ and νe→ ντ oscillation
Rulander et al. Interference from anti-streptavidin antibody
RU2011141499A (ru) Способ определения пола птиц
AR103935A1 (es) Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th-2
DE602005019552D1 (de) Eliminierung von cross-talk in einem mehrere quellen umfassenden rückstreuungs-inspektionsportal durch sicherstellen, dass zu einem zeitpunkt jeweils nur eine quelle strahlung emittiert
ATE532051T1 (de) Differenzielle reflexionsspektroskopieverfahren zur erkennung von sprengstoffen
MX2025009080A (es) Analizador de concentracion en el punto de atencion
GB2525114A (en) Improved method for rapid analysis of gold
AR124434A1 (es) Métodos para la detección de anticuerpos antifármaco contra anticuerpos factor xi y/o factor xia
MX357292B (es) Método para detectar cáncer.
MX2024008320A (es) Biomarcadores transcripcionales para la respuesta a activadores inmunitarios innatos
WO2022020733A3 (en) System and methods for detection of pathogenic viruses
NZ630856A (en) Mitochondrial toxicity test
Ahrens et al. Measurement of the helicity dependence for the γ p→ n π+ channel in the second resonance region
US20130043398A1 (en) System and method for assaying a radionuclide
Song et al. Flow injection chemiluminescence immunosensor for the determination of clenbuterol by immobilizing coating-antigen on carboxylic resin beads
Daungsupawong et al. Enhancing the accuracy of seroprevalence studies: reassessing pertussis infection rates in eastern China during the COVID-19 pandemic
Sun et al. Pseudo Elevation of TSH and ACTH Caused by Heterophilic Antibodies: a Case Report and Literature Review.
ES2131279T3 (es) Inmunoensayo de tipo sandwich para n-peptido.
de Souza Nogueira et al. Metabolic adaptations correlated with antibody response after immunization with inactivated SARS-CoV-2 in Brazilian subjects
WO2009107464A1 (ja) 核物質検出装置、核物質検査システムおよびクリアランス装置
Sun et al. Reply to the enhancing the accuracy of seroprevalence studies: Reassessing pertussis infection rates in Eastern China during the COVID-19 pandemic
CA2409208A1 (en) Method for examining wt1-related disease
Fan et al. Negative interference by rheumatoid factor of plasma B-type natriuretic peptide in chemiluminescent microparticle immunoassays
WO2022013321A3 (en) Use of antigen combination for detecting autoantibodies in lung cancer